Correct usage, ease of use, and preference of two dry powder inhalers in patients with COPD: analysis of five phase III, randomized trials

References

• ManninoDMBuistASGlobal burden of COPD: risk factors, prevalence, and future trendsLancet2007370958976577317765526
   PubMed Web of Science ®Google Scholar
• PriceDBosnic-AnticevichSBriggsAInhaler competence in asthma: common errors, barriers to use and recommended solutionsRespir Med20131071374623098685
   PubMed Web of Science ®Google Scholar
• HammerleinAMullerUSchulzMPharmacist-led intervention study to improve inhalation technique in asthma and COPD patientsJ Eval Clin Pract2011171617020807295
   PubMed Web of Science ®Google Scholar
• RestrepoRDAlvarezMTWittnebelLDMedication adherence issues in patients treated for COPDInt J Chron Obstruct Pulmon Dis20083337138418990964
   PubMedGoogle Scholar
• BrocklebankDRamFWrightJComparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literatureHealth Technol Assess2001526114911701099
   PubMedGoogle Scholar
• HanselTTBarnesPJNew drugs and targets for asthma and COPDBolligerCTProgress in Respiratory ResearchLondonKarger2010
   Google Scholar
• TakiMMarriottCZengXMMartinGPThe aerodynamic deposition of drugs from combination DPI formulations: the influence of particle size and drug-drug interactionsJ Aerosol Med Pulm Drug Deliv200922285306
   Google Scholar
• GrantACWalkerRHamiltonMGarrillKThe ELLIPTA® dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregiversJ Aerosol Med Pulm Drug Deliv201528647448526372466
   PubMed Web of Science ®Google Scholar
• WoodcockALotvallJBusseWWEfficacy and safety of fluticasone furoate 100 mug and 200 mug once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised studyBMC Pulm Med20141411325007865
   PubMed Web of Science ®Google Scholar
• KerwinEMScott-WilsonCSanfordLA randomised trial of fluticasone furoate/vilanterol (50/25 mug; 100/25 mug) on lung function in COPDRespir Med2013107456056923352226
   PubMed Web of Science ®Google Scholar
• MartinezFJBosciaJFeldmanGFluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trialRespir Med2013107455055923332861
   PubMed Web of Science ®Google Scholar
• CalverleyPMADransfieldMTBourbeauJSafety of fluticasone fuorate (FF), an inhaled corticosteroid in combination with vilanterol (VI), a long-acting beta agonist in management of COPD exacerbationsEur Respir J201240Suppl 562113
   Google Scholar
• DransfieldMTBourbeauJJonesPWOnce-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trialsLancet Respir Med20131321022324429127
   PubMed Web of Science ®Google Scholar
• DonohueJFKalbergCShahPDose response of umeclidinium administered once or twice daily in patients with COPD: a pooled analysis of two randomized, double-blind, placebo-controlled studiesJ Clin Pharmacol201454111214122024895108
   PubMed Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med2013107101538154623830094
   PubMed Web of Science ®Google Scholar
• DonohueJFNiewoehnerDBrooksJO’DellDChurchASafety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled studyRespir Res2014157825015176
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• TrivediRRichardNMehtaRChurchAUmeclidinium in patients with COPD: a randomised, placebo-controlled studyEur Respir J2014431728123949963
   PubMed Web of Science ®Google Scholar
• SvedsaterHDalePGarrillKWalkerRWoepseMWQualitative assessment of attributes and ease of use of the ELLIPTA dry powder inhaler for delivery of maintenance therapy for asthma and COPDBMC Pulm Med2013137224314123
   PubMed Web of Science ®Google Scholar
• MaltaisFSinghSDonaldACEffects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trialsTher Adv Respir Dis20148616918125452426
   PubMed Web of Science ®Google Scholar
• Maleki-YazdiMRKaelinTRichardNZvarichMChurchAEfficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trialRespir Med2014108121752176025458157
   PubMed Web of Science ®Google Scholar
• ClarkMHofmannATabbererMMartinSDevelopment and content validity of the COPD device preference questionnaireValue Health2011147PA255
   Web of Science ®Google Scholar
• MelaniASBonaviaMCilentiVInhaler mishandling remains common in real life and is associated with reduced disease controlRespir Med2011105693093821367593
   PubMed Web of Science ®Google Scholar
• LareauSCYawnBPImproving adherence with inhaler therapy in COPDInt J Chron Obstruct Pulmon Dis2010540140621191434
   PubMedGoogle Scholar
• LavoriniFFontanaGAInhaler technique and patient’s preference for dry powder inhaler devicesExpert Opin Drug Deliv20141111324093806
   PubMed Web of Science ®Google Scholar
• FromerLGoodwinEWalshJCustomizing inhaled therapy to meet the needs of COPD patientsPostgrad Med20101222839320203459
   PubMed Web of Science ®Google Scholar
• AndersonPPatient preference for and satisfaction with inhaler devicesEur Respir Rev20051496109116
   Google Scholar
• HodderRPriceDPatient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhalerInt J Chron Obstruct Pulmon Dis2009438139019888356
   PubMedGoogle Scholar